- Home
- APP vs SNY Comparison
APP vs SNY Comparison
Compare APP & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APP | SNY |
|---|---|---|
| Founded | 2012 | 1994 |
| Country | United States | France |
| Employees | N/A | 74846 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.6B | 116.8B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | APP | SNY |
|---|---|---|
| Price | $463.04 | $44.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 6 |
| Target Price | ★ $703.71 | $61.50 |
| AVG Volume (30 Days) | ★ 5.6M | 4.3M |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.64% |
| EPS Growth | ★ 115.23 | N/A |
| EPS | ★ 9.75 | N/A |
| Revenue | ★ $5,480,717,000.00 | N/A |
| Revenue This Year | $47.55 | $3.01 |
| Revenue Next Year | $29.08 | $5.80 |
| P/E Ratio | $49.00 | ★ $6.14 |
| Revenue Growth | ★ 16.38 | N/A |
| 52 Week Low | $200.50 | $43.51 |
| 52 Week High | $745.61 | $59.17 |
Technical Indicators
Market Signals| Indicator | APP | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 49.08 | 32.88 |
| Support Level | $344.94 | N/A |
| Resistance Level | $473.69 | $48.97 |
| Average True Range (ATR) | 26.44 | 0.68 |
| MACD | 12.93 | -0.38 |
| Stochastic Oscillator | 62.11 | 8.60 |
Price Performance
Historical ComparisonAbout APP Applovin Corporation
AppLovin is a vertically integrated advertising technology company that acts as a demand-side platform for advertisers, a supply-side platform for publishers, and an exchange facilitating transactions between the two. About 80% of AppLovin's revenue comes from the DSP, AppDiscovery, while the remainder comes from the SSP, Max. AppLovin's primary tool for future growth is AXON 2, which is an ad optimizer operating within the DSP that allows advertisers to place ads according to specified return thresholds.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.